<DOC>
	<DOCNO>NCT00676715</DOCNO>
	<brief_summary>This phase II , multicenter , randomize , parallel-group , partially blind , placebo Avonex ( interferon beta-1a ) control dose finding study evaluate efficacy measure brain MRI lesion , safety 2 dose regimen ocrelizumab patient RRMS .</brief_summary>
	<brief_title>A Study Efficacy Safety Ocrelizumab Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Ability provide write informed consent compliant schedule protocol assessment Relapsingremitting MS Ages 1855 year inclusive For sexually active female male patient reproductive potential , use reliable mean contraception Secondary primary progressive multiple sclerosis screen Incompatibility MRI Contraindications intolerance oral i.v . corticosteroid Known presence neurologic disorder Pregnancy lactation Lack peripheral venous access History severe allergic anaphylactic reaction humanize murine monoclonal antibody Significant , uncontrolled disease , cardiovascular , pulmonary , renal , hepatic , endocrine gastrointestinal Congestive heart failure Known active bacterial , viral , fungal , mycobacterial infection infection major episode infection require hospitalization treatment i.v . antibiotic within 4 week prior screen oral antibiotic within 2 week prior screen History know presence recurrent chronic infection History cancer , include solid tumor hematological malignancy ( except basal cell , situ squamous cell carcinoma skin , situ carcinoma cervix uterus excise resolve ) History alcohol drug abuse within 24 week prior randomization History currently active primary secondary immunodeficiency History coagulation disorder Treatment investigational agent within 4 week screen Receipt live vaccine within 6 week prior randomization Incompatibility Avonex use Previous treatment rituximab Previous treatment lymphocytedepleting therapy except mitoxantrone Treatment lymphocyte traffic blocker within 24 week prior randomization Treatment beta interferon , glatiramer acetate , i.v . immunoglobulin , plasmapheresis , immunosuppressive therapy within 12 week prior randomization Systemic corticosteroid therapy within 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>